10 Top Oncology Companies

10大肿瘤公司

2020-12-03 05:31:08 Investing News Network

本文共2672个字,阅读需7分钟

The oncology market covers every area of cancer care, from diagnosis to treatment, and is one of the biggest sectors in the life science space. Cancer is the second leading cause of death worldwide, after cardiovascular diseases. Biotechnology and pharmaceutical companies alike are working to develop best-in-class therapeutics for the treatment of various cancers, including lung cancer, breast cancer and prostate cancer. Deloitte’s latest life science outlook states that global prescription drug sales are expected to have a compound annual growth rate (CAGR) of 6.9 percent from 2019 to 2024 to reach US$1.18 trillion. Oncology drugs are projected to corner nearly 20 percent of the market with a CAGR of 11.4 percent. Investors interested in stocks in the global oncology market should take a look at biotech and pharmaceutical companies with a focus on oncology drugs and testing. This list of A-rated oncology stocks on the NASDAQ was gathered through SwingTradeBot.com. The top oncology companies are listed in order of market cap, and all figures below were current as of market close on November 2, 2020. Market cap: US$11.42 billion; current share price: US$112.16 First on our top oncology companies list is NovoCure, a commercial-stage oncology company pioneering a novel therapy for solid tumors called Tumor Treating Fields (TTFields). TTFields uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. For the third quarter of 2020, NovoCure reported net revenues of US$132.7 million, representing 44 percent growth over Q3 2019 and 14 percent growth over Q2 2020. Its quarterly net income was came to US$9.3 million with US$0.09 in earnings per share. Market cap: US$10.47 billion; current share price: US$105.09 Guardant Health is a precision oncology company that is developing proprietary blood tests for the early detection of tumor DNA in high-risk populations and recurrence monitoring in cancer survivors. In October 2020, the company announced that via a new study focusing on gastrointestinal cancer, its technology for analyzing circulating tumor DNA has demonstrated the potential to both speed up and increase the enrollment of cancer patients into clinical trials. Market cap:US$9.17 billion; current share price: US$216.75 Mirati Therapeutics is a clinical-stage oncology company that is developing therapies to address the genetic and immunological causes of cancer. Mirati has a clinical collaboration agreement with multinational pharmaceutical giant Novartis International (NYSE:NVS). Mirati has several drug candidates in its pipeline, including a KRAS G12C inhibitor in a Phase 2/3 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic and other cancers. Recent results from the KRAS G12C inhibitor trial show that 45 percent of participants had an objective response to the therapy. The company is also working on sitravatinib, a spectrum-selective kinase inhibitor in a Phase 2 clinical trial for the treatment of NSCL cancer. Market cap: US$5.34 billion; current share price: US$36.44 Iovance Biotherapeutics is a clinical-stage biopharmaceutical company developing T cell-based immuno-oncology tumor-infiltrating lymphocyte (TIL) therapies for cancer. TIL therapies use a patient’s own immune cells to attack cancer cells. The company plans to submit a biologics license application for lifileucel, its investigative TIL therapy for metastatic melanoma, to the US Food and Drug Administration in 2021. Market cap: US$4.49 billion; current share price: US$70.38 Berkeley Lights is a biotech company focused on cellular therapy, biopharmaceuticals and genomics. The company has developed a tech platform for the rapid functional characterization of single cells at scale. Developing and commercializing T cell therapies — which have shown to be highly effective in fighting cancerous tumors — has proved challenging because of the time-consuming and complex procedure required for the process of studying and screening multiple cell-to-cell interactions. Berkeley Lights’ technology has the potential to significantly reduce this time and complexity. Berkeley Lights went public in July 2020 after launching a successful IPO that raised US$205 million; that was more than double the company’s US$100 million filing. Market cap: US$2.99 billion; current share price: US$29.38 Burning Rock Biotech is a biotech company specializing in next-generation sequencing (NGS) diagnostics solutions for precision medicine in oncology. The company is focused on NGS-based therapy selection testing for late-stage cancer patients, especially in China. In November 2020, Burning Rock presented new data for its early detection ELSA-seq test at the European Society for Medical Oncology Asia Virtual Congress. The ELSA-seq test is a blood-based targeted methylation sequencing test that interrogates the epigenetic alterations from circulating cell-free DNA to allow for sensitive detection and accurate localization of early stage tumors. Market cap: US$1.77 billion; current share price: US$31.38 Kura Oncology is a clinical-stage biopharmaceutical company that is developing a pipeline of precision medicines for the treatment of solid tumors and blood cancers. Kura’s lead product candidate, Tipifarnib, is in Phase 2 clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas and other hematologic malignancies. In October 2020, new preclinical data demonstrated that Kura’s late-stage drug candidate, tipifarnib, “shows compelling activity when combined with a PI3Kα inhibitor in models of HRAS.” Market cap: US$500.54 million; current share price: US$15.89 Cardiff Oncology is a clinical-stage biotechnology company developing treatment options for various cancers, including including KRAS-mutated colorectal cancer, castration-resistant prostate cancer and leukemia. The company’s primary drug candidate is onvansertib, a highly-selective PLK1 inhibitor for the treatment of solid tumor and hematologic cancers. Currently in Phase 2 trials, highlights from recent efficacy and safety results for onvansertib in metastatic castration-resistant prostate cancer include 31 percent of evaluable patients achieving the primary endpoint of disease control after 12 weeks of treatment. Market cap: US$394.26 million; current share price: US$3.79 Aspira Women’s Health is a biotech company focused on developing testing and treatments for gynecologic issues, including ovarian cancer. According to the company, “detecting ovarian cancer in Black women presents physicians with many challenges, as testing is less sensitive in that population.” Aspira is working to close the gap between these disparities in ovarian cancer detection. The company’s OVA1plus, a reflex process combining OVA1 and Overa, is a multivariate biomarker for assessing ovarian cancer risk in women across all ethnicities. In October 2020, Aspira announced that it is now a participating provider for Anthem BlueCross BlueShield of Georgia, which covers approximately 3.3 million members across the state. Market cap: US$185.86 million; current share price: US$7.33 Fennec Pharmaceuticals is a biopharmaceutical company developing cancer drugs. The company has completed patient enrollment of over two Phase 3 clinical trials for its lead product candidate, sodium thiosulfate (STS) for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. STS is under review with the US Food and Drug Administration and European Medicines Agency. This is an updated version of an article first published by the Investing News Network in 2018. Don’t forget to follow us @INN_LifeScience for real-time updates! Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.
肿瘤学市场涵盖了癌症治疗的各个领域,从诊断到治疗,是生命科学领域最大的领域之一。 癌症是全世界第二大死亡原因,仅次于心血管疾病。生物技术和制药公司都在致力于开发一流的治疗药物,用于治疗各种癌症,包括肺癌,乳腺癌和前列腺癌。 德勤最新的《生命科学展望》指出,2019年至2024年,全球处方药销售额的复合年增长率(CAGR)预计为6.9%,达到1.18万亿美元。肿瘤药物预计将占据近20%的市场,复合增长率为11.4%。 对全球肿瘤市场股票感兴趣的投资者应该看一看生物技术和制药公司,重点关注肿瘤药物和检测。 这份纳斯达克A级肿瘤股票的名单是通过SwingTradebot.com收集的。排名靠前的肿瘤公司按市值排序,以下所有数据均为截至2020年11月2日收盘时的最新数据。 市值:114.2亿美元;当前股价:112.16美元 排名第一的肿瘤公司是NovoCure,一家商业阶段的肿瘤公司,开创了一种叫做Tumor Treating Fields(TTFields)的实体肿瘤新疗法。TTFields利用调谐到特定频率的电场来扰乱实体肿瘤癌细胞的分裂。 2020年第三季度,NovoCure报告净收入为1.327亿美元,比2019年第三季度增长44%,比2020年第二季度增长14%。其季度净收入达到930万美元,每股收益为0.09美元。 市值:104.7亿美元;当前股价:105.09美元 Guardant Health是一家精密肿瘤学公司,正在开发专有的血液测试,用于高危人群肿瘤DNA的早期检测和癌症幸存者的复发监测。 2020年10月,该公司宣布,通过一项专注于胃肠道癌症的新研究,其用于分析循环肿瘤DNA的技术已经证明了加快和增加癌症患者参与临床试验的潜力。 市值:91.7亿美元;当前股价:216.75美元 Mirati Therapeutics是一家临床阶段的肿瘤学公司,正在开发治疗癌症的遗传和免疫学原因。Mirati与跨国制药巨头诺华国际公司(NYSE:NVS)签订了临床合作协议。 Mirati有几种候选药物在研发中,包括一种KRAS G12C抑制剂,正在进行2/3期临床试验,用于治疗非小细胞肺(NSCL),结直肠,胰腺和其他癌症。KRAS G12C抑制剂试验的最新结果显示,45%的参与者对该疗法有客观的反应。该公司还在研究sitravatinib,这是一种光谱选择性激酶抑制剂,用于治疗NSCL癌的2期临床试验。 市值:53.4亿美元;目前股价:36.44美元 Iovance生物治疗公司是一家临床阶段的生物制药公司,开发基于T细胞的免疫肿瘤学肿瘤浸润淋巴细胞(TIL)疗法治疗癌症。TIL疗法利用患者自身的免疫细胞来攻击癌细胞。 该公司计划于2021年向美国食品和药物管理局提交其用于转移性黑色素瘤的研究性TIL疗法lifileucel的生物制剂许可申请。 市值:44.9亿美元;当前股价:70.38美元 Berkeley Lights是一家专注于细胞治疗,生物制药和基因组学的生物技术公司。该公司已经开发了一个技术平台,用于快速功能表征单细胞规模。 由于研究和筛选多种细胞间相互作用的过程需要耗时和复杂的程序,T细胞疗法的开发和商业化已被证明具有挑战性,T细胞疗法已被证明在对抗癌症肿瘤方面非常有效。Berkeley Lights的技术有潜力显著减少这一时间和复杂性。 伯克利照明公司于2020年7月上市,此前成功启动IPO,筹资2.05亿美元;这是该公司申报的1亿美元的两倍多。 市值:29.9亿美元;目前股价:29.38美元 Burning Rock Biotech是一家专注于肿瘤精准医疗的下一代测序(NGS)诊断解决方案的生物技术公司。该公司专注于晚期癌症患者基于NGS的治疗选择测试,尤其是在中国。 2020年11月,Burning Rock在欧洲医学肿瘤学会亚洲虚拟大会上展示了其早期检测ELSA-seq测试的新数据。ELSA-seq试验是一种基于血液的靶向甲基化测序试验,它询问来自循环无细胞DNA的表观遗传改变,以便敏感地检测和准确地定位早期肿瘤。 市值:17.7亿美元;目前股价:31.38美元 Kura Oncology是一家临床阶段的生物制药公司,正在开发一系列用于治疗实体肿瘤和血癌的精确药物。Kura的主要候选产品Tipifarnib正处于治疗实体瘤,外周T细胞淋巴瘤和其他血液系统恶性肿瘤的2期临床试验。 2020年10月,新的临床前数据表明,Kura的晚期候选药物tipifarnib“在HRA模型中与PI3 Ka抑制剂联合使用时显示出令人信服的活性。” 市值:50054万美元;目前股价:15.89美元 Cardiff Oncology是一家临床阶段的生物技术公司,开发各种癌症的治疗方案,包括KRAS突变的结直肠癌,抗去势的前列腺癌和白血病。该公司的主要候选药物是onvansertib,这是一种高选择性PLK1抑制剂,用于治疗实体瘤和血液系统癌症。 目前在2期试验中,onvansertib治疗转移性去势耐药前列腺癌的近期疗效和安全性结果的亮点包括31%的可评估患者在治疗12周后达到了疾病控制的主要终点。 市值:3.9426亿美元;目前股价:3.79美元 阿司匹拉妇女健康公司是一家生物技术公司,专注于发展妇科问题的测试和治疗,包括卵巢癌。阿司匹拉公司表示,“在黑人妇女中检测卵巢癌给医生带来了许多挑战,因为检测在该人群中不太敏感。”阿司匹拉公司正在努力缩小卵巢癌检测中的这些差异。该公司的OVA1plus是一种结合OVA1和Overa的反射过程,是评估所有种族妇女卵巢癌风险的多变量生物标志物。 2020年10月,阿司匹拉宣布,它现在是佐治亚州Anthem BlueCross BlueShield的参与供应商,该公司覆盖全州约330万会员。 市值:18586万美元;目前股价:7.33美元 芬耐克制药是一家开发癌症药物的生物制药公司。该公司已经完成了两个以上3期临床试验的患者登记,该试验的主要候选产品是硫代硫酸钠(STS),用于预防顺铂引起的儿童听力损失或耳毒性。美国食品药品管理局和欧洲药品管理局正在对STS进行审查。 本文是投资新闻网2018年首次发表的一篇文章的更新版本。 别忘了关注我们@inn_lifescience的实时更新! 证券披露:本人,Melissa Pistilli,在本文提及的任何公司中均不持有直接投资权益。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文